Investors & partners
Buy the delivery key and the human dataset for a molecule the world has just validated
An investment in Cholrem is not a bet on a single product. It is a position in the practical delivery of HPβCD across vascular and neurodegenerative medicine, backed by the only human cardiovascular data in existence, at the moment the field has become real.
The opportunity
Why now
The molecule is FDA-approved
Lembaz™ made HPβCD a US-licensed medicine in November 2026, for intrathecal use in Niemann-Pick type C. Systemic safety rests on more than a decade of high-dose intravenous use in the same disease, and an intravenous HPβCD application is now before the FDA. The regulatory question is no longer “is this molecule a medicine?” but “who has the data for the next indication?”
The coronary race has started
Cyclarity has FDA clearance for a Phase 1b in coronary artery disease with CT imaging endpoints. Rafael has filed an intravenous HPβCD application. Big biotech is spending to reach a place Cholrem already occupies.
Cholrem is eight years ahead
Human coronary imaging, a practical chronic formulation, thousands of users, a registry, six papers and a 2019 public disclosure that predates the field’s patents. Nobody can buy that time back.
Companies have raised tens to hundreds of millions of dollars chasing results Cholrem has already achieved in human arteries.
Beren raised US$300 million in 2026. Its patent filings on treating cardiovascular disease with cyclodextrins date from August 2020, more than a year after Cholrem’s public disclosure. Cyclarity begins its first coronary patient study in 2027. Neither has published human arterial imaging. Cholrem has, across its published papers.
Where everyone stands
| Cholrem | Beren | Rafael | Cyclarity | |
|---|---|---|---|---|
| Molecule | HPβCD, as Cavadex® | HPβCD, as Lembaz™ | HPβCD, as Trappsol Cyclo | Engineered cyclodextrin, UDP-003 |
| How it is given | Rectally, at home, nightly | Into the spinal fluid, in hospital | Intravenous infusion, in hospital | Intravenous infusion |
| Disease in view | Coronary and arterial disease | Niemann-Pick type C | Niemann-Pick type C | Coronary artery disease |
| Stage | In human use since 2020 | FDA approved, November 2026 | FDA application filed, October 2026 | First patient study cleared, starts 2027 |
| Published human arterial imaging | Yes: coronary, carotid and peripheral | None | None | None yet |
| Human use in arterial disease | 4,000+ users | None reported | None reported | None yet |
What Cholrem brings
The assets
| Asset | What it is | Why it matters |
|---|---|---|
| Human cardiovascular dataset | Six published papers, a case report in peer review, serial imaging and calcium scores, a 125-person observational cohort and a growing member registry. | The only human arterial data for HPβCD anywhere. The starting point for any cardiovascular program. |
| Delivery formulation | Patent-pending high-viscosity rectal formulation enabling nightly, at-home, chronic systemic dosing. Quad Strength generation in use. | Solves the problem that confines every other cyclodextrin program to hospital infusion or spinal injection. |
| Manufacturing know-how | Eight years of formulation, sourcing and production experience with pharmaceutical-grade HPβCD. | Shortens a partner’s path to GMP supply. |
| User base and registry | 4,000+ users since 2020, 10,000-person contact list, three in four orders from returning users, built by word of mouth with no advertising, Members Circle with structured data capture. | A ready trial-recruitment pool and a real-world evidence engine. |
| Safety record | No hearing loss reported across 4,000+ users since 2020. Published audiometry in the founder was normal after intravenous infusions of up to 80 grams. The hearing signal seen in NPC belongs to intrathecal dosing and to very high intravenous doses repeated for months, not to Cavadex’s route or dose. | Takes the one known class liability off the table for the route Cholrem uses. Audiometry will also be built into any formal study. |
| Prior art position | Public disclosure of HPβCD in human atherosclerosis from 2019, archived and dated. | Freedom to operate, and leverage against later-filed cardiovascular cyclodextrin patents. |
| Brand and story | Cavadex® trademark, an eight-year founder story, video record, and a patient base that speaks for itself. | Commercial traction before a single trial dollar is spent. |
The moat
Why it cannot be copied
Only Cavadex is proven
HPβCD is not a single product. The US National Institutes of Health trial team wrote in The Lancet that its composition varies with the source, and that “one cannot assume that all HPβCD formulations are equivalent” in efficacy or toxicity. Cavadex has used one manufacturer’s HPβCD for all eight years. The one time another maker’s material was tried, the infusion had to be stopped, as Cholrem’s 2019 paper records. Cavadex, made Cholrem’s way, is the one with human arterial results. How it is made has never been published, and the formulation is patent pending.
The date is on record
Cholrem publicly disclosed HPβCD treatment of human atherosclerosis in 2019, and the Internet Archive holds dated copies. Patents filed later on the same use have to get past that date.
The time cannot be bought
Eight years of work, 4,000+ users and the only human arterial imaging for the molecule. A competitor starting today needs years of human use to stand where Cholrem stands.
What comes next
The next step is open
Cholrem has done what no funded program has: generated a human clinical signal. What happens next depends on the partner. Cholrem is open on route, scale and structure, and will shape the next stage around what the right partner wants to achieve.
Regulatory status, stated plainly
Cavadex has been supplied to the public in Australia and internationally since 2020 in response to patient demand, outside the conventional registration pathway. The regulatory history is available in full in the data room, as it would be in any diligence process.
Structures
Ways to work together
Licence
Territory or indication licence to the formulation, data and know-how, with milestone and royalty terms.
Co-development
A partner funds the next stage of development. Cholrem contributes the formulation, the data, the user base and the know-how.
Equity investment
Capital into Cholrem itself.
Acquisition
Full acquisition of Cholrem’s data, IP, brand and user base.
Something else
If you see another way to work with Cholrem, tell us.
Cholrem was there first, and holds the cards that matter.
The human arterial data, the formulation, the date on the record and the users all sit in one company. The first partner to move takes the lead position in a field the rest of the industry is paying to enter.
Open the data room
Qualified investors and development partners receive the full publication set, the registry summary, the regulatory file and, under agreement, the DICOM imaging series.